MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.52
-0.38
-4.81%
After Hours: 7.32 -0.2 -2.66% 19:20 05/11 EDT
OPEN
7.65
PREV CLOSE
7.90
HIGH
7.73
LOW
7.09
VOLUME
6.99M
TURNOVER
--
52 WEEK HIGH
12.44
52 WEEK LOW
3.550
MARKET CAP
861.70M
P/E (TTM)
-12.0706
1D
5D
1M
3M
1Y
5Y
BRIEF-Dynavax Announces Pricing Of $200 Million Convertible Senior Notes Offering
reuters.com · 17h ago
Dynavax Technologies Prices Convertible Senior Note Offering
MT Newswires · 19h ago
64 Biggest Movers From Yesterday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 82.6% to settle at $6.39 on Monday.
Benzinga · 20h ago
PRTY, TTD, PRPO and WKHS among midday movers
Gainers: Protagenic Therapeutics (PTIX) +67%.Obalon Therapeutics (OBLN) +57%.Precipio (PRPO) +35%.Cue Biopharma (CUE) +31%.SemiLEDs (LEDS) +28%.CKX Lands (CKX) +27%.Tecnoglass (TGLS) +24%.Soliton (SOLY) +24%.Party City Holdco (PRTY) +19%.uCloudlink (UCL) +...
Seekingalpha · 1d ago
40 Stocks Moving In Monday's Mid-Day Session
Gainers Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares jumped 64.2% to $3.4962 on above-average news.
Benzinga · 1d ago
DJ Dynavax Technologies Shares Drop 12% After Private Placement of Notes
Dow Jones · 1d ago
Dynavax shares down 6% on launch of $200M debt offering
Dynavax Technologies (DVAX) intends to offer, $200M aggregate principal amount of convertible senior notes due 2026 in a private placement.Initial purchasers will be granted an option to purchase up to
Seekingalpha · 1d ago
Dynavax Tech Plans $200 Million Convertible Senior Notes Offering; Stock Slumps
MT Newswires · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Techs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DVAX stock price target is 18.67 with a high estimate of 20.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 101.85M
% Owned: 88.90%
Shares Outstanding: 114.59M
TypeInstitutionsShares
Increased
54
7.25M
New
11
137.88K
Decreased
43
8.83M
Sold Out
31
2.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Andrew Hack
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Kelly MacDonald
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Steven Gersten
Senior Vice President/Director of Human Resources
Jeff Coon
Senior Vice President
Robert Janssen
Senior Vice President
Dong Yu
Chief Accounting Officer
Justin Burgess
Director
Julie Eastland
Director
Brent MacGregor
Director
Peter Paradiso
Independent Director
Francis Cano
Independent Director
Daniel Kisner
Independent Director
Arnold Oronsky
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
No Data
About DVAX
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.